促炎细胞因子
细胞因子
细胞
癌症研究
抗体
医学
免疫学
化学
炎症
生物化学
作者
Katja Klausz,Lukas Pekar,Ammelie Svea Boje,Carina Lynn Gehlert,Steffen Krohn,Tushar Gupta,Yanping Xiao,Simon Krah,Rinat Zaynagetdinov,Britta Lipinski,Lars Toleikis,Sven Poetzsch,Brian Rabinovich,Matthias Peipp,Stefan Zielonka
出处
期刊:Journal of Immunology
[The American Association of Immunologists]
日期:2022-11-01
卷期号:209 (9): 1724-1735
被引量:16
标识
DOI:10.4049/jimmunol.2100970
摘要
Abstract In this work, we have generated novel Fc-comprising NK cell engagers (NKCEs) that bridge human NKp30 on NK cells to human epidermal growth factor receptor (EGFR) on tumor cells. Camelid-derived VHH single-domain Abs specific for human NKp30 and a humanized Fab derived from the EGFR-specific therapeutic Ab cetuximab were used as binding arms. By combining camelid immunization with yeast surface display, we were able to isolate a diverse panel of NKp30-specific VHHs against different epitopes on NKp30. Intriguingly, NKCEs built with VHHs that compete for binding to NKp30 with B7-H6, the natural ligand of NKp30, were significantly more potent in eliciting tumor cell lysis of EGFR-positive tumor cells than NKCEs harboring VHHs that target different epitopes on NKp30 from B7-H6. We demonstrate that the NKCEs can be further improved with respect to killing capabilities by concomitant engagement of FcγRIIIa and that soluble B7-H6 does not impede cytolytic capacities of all scrutinized NKCEs at significantly higher B7-H6 concentrations than observed in cancer patients. Moreover, we show that physiological processes requiring interactions between membrane-bound B7-H6 and NKp30 on NK cells are unaffected by noncompeting NKCEs still eliciting tumor cell killing at low picomolar concentrations. Ultimately, the NKCEs generated in this study were significantly more potent in eliciting NK cell–mediated tumor cell lysis than cetuximab and elicited a robust release of proinflammatory cytokines, both features which might be beneficial for antitumor therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI